K. Kane

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.

Scott E. Smith, L. Gordon, J. Winter, 2023, JAMA oncology.

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

L. Gordon, J. Winter, J. Chmiel, 2022, Blood advances.

Race-Associated Genomic Correlates of Therapeutic Response in African American Patients With Non-Small-Cell Lung Cancer.

S. Gadgeel, A. Berry, Pin Li, 2023, JCO Precision Oncology.